Sort by
Keyphrases
Ovarian Cancer
100%
Advanced Cancer
100%
Phase II Trial
100%
Peritoneum
100%
First-line Therapy
100%
Measurable Disease
100%
Fallopian Tube
100%
Bevacizumab
100%
Oxaliplatin
100%
Docetaxel
100%
Response Rate
50%
Progression-free Survival
50%
Novel Treatments
25%
Therapeutic Approaches
25%
Treatment Regimen
25%
Hypertension
25%
Novel Combinations
25%
Working Diagnosis
25%
Adverse Events
25%
Debulking Surgery
25%
Nausea
25%
Carbohydrate Antigen 125 (CA125)
25%
Primary Peritoneal
25%
Complete Response
25%
Safety Concerns
25%
Partial Response
25%
Neutropenia
25%
Median Progression-free Survival
25%
6-cycles
25%
Median Overall Survival
25%
Leukopenia
25%
Stage III Disease
25%
Fallopian Tube Carcinoma
25%
Intestinal Perforation
25%
Stage IB
25%
Medicine and Dentistry
Advanced Cancer
100%
Phase II Trials
100%
Peritoneum
100%
Oxaliplatin
100%
Docetaxel
100%
Bevacizumab
100%
Diseases
100%
Fallopian Tube
100%
Progression Free Survival
50%
Adverse Event
16%
Survival Rate
16%
Overall Survival
16%
Debulking Surgery
16%
Cytoreductive Surgery
16%
CA-125
16%
Neutropenia
16%
Nausea
16%
Leukopenia
16%
Gastrointestinal Perforation
16%
Uterine Tube Carcinoma
16%
Pharmacology, Toxicology and Pharmaceutical Science
Phase II Trials
100%
Bevacizumab
100%
Oxaliplatin
100%
Advanced Cancer
100%
Docetaxel
100%
Diseases
100%
Progression Free Survival
50%
Adverse Event
16%
Survival Rate
16%
Overall Survival
16%
Neutropenia
16%
Nausea
16%
Leukopenia
16%
Digestive System Perforation
16%
Uterine Tube Carcinoma
16%